Education
About Us
Working with TipRanks
Follow Us
HeartBeam (BEAT)
NASDAQ:BEAT
BEAT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.17 - $3.48
Previous CloseN/A
Volume12.23K
Average Volume (3M)129.29K
Market Cap
$42.26M
Enterprise Value$37.87M
Total Cash (Recent Filing)$4.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 07, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding33,809,708
10 Day Avg. Volume49,070
30 Day Avg. Volume129,295
Financial Highlights & Ratios
PEG Ratio1.34
Price to Book (P/B)4.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$8.00Price Target Upside540.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
HeartBeam News
PremiumCompany Announcements
HeartBeam Holds Virtual Annual Stockholders Meeting
PremiumTipRanks Newswire
HeartBeam (NASDAQ: BEAT) Is ‘One to Watch’
PremiumCompany Announcements
HeartBeam’s Positive Earnings Call Reflects Growth Potential
PremiumCompany Announcements
HeartBeam, Inc. Reports Q1 2025 Financial ResultsBulls Say, Bears Say
Bulls Say
Regulatory ApprovalHeartBeam’s proprietary system for arrhythmia assessment received 510(k) clearance from the FDA, enhancing its credibility and market potential.
Strategic CollaborationA strategic collaboration was signed with AccurKardia to add AccurECG algorithm to HeartBeam’s device, facilitating quicker diagnosis and faster access to clinical care.
Technological AdvancementsHeartBeam received clearance for its core system, the first patient-held device leveraging vector technology that captures the heart’s electrical signals in three dimensions, offering significant diagnostic improvements.
Bears Say
Financial PerformanceCash used in operating activities was $4.5M, indicating significant expenses in the first quarter.
Options Prices
Currently, No data available
---
Ownership Overview
15.36% Insiders
3.05% Mutual Funds
2.81% Other Institutional Investors
76.13% Public Companies and
Individual Investors
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $1.17 and its highest was $3.48 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $42.26M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Aug 07, 2025 which is in 20 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on May 13, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.03.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.18.
How many shares outstanding does HeartBeam have?
HeartBeam has 33,809,708 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -6.433%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
HeartBeam Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (540.00% Upside)
$8.00 (540.00% Upside)
Blogger Sentiment
Bullish
BEAT Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.35%
12-Months-Change
Fundamentals
Return on Equity
-202.58%
Trailing 12-Months
Asset Growth
-33.21%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc. (BEAT) is a healthcare technology company focused on developing advanced solutions for cardiovascular disease detection and management. Operating in the medical device sector, the company specializes in creating innovative, portable, and easy-to-use heart monitoring products aimed at improving patient outcomes and reducing healthcare costs. Its core offerings include a proprietary system designed to enable users to take a 12-lead electrocardiogram (ECG) outside of a medical setting and transmit the data to healthcare providers.
BEAT Company Deck
BEAT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant advancements in regulatory approvals, strategic collaborations, and commercial readiness efforts. While there are challenges related to financial constraints and dependencies on partnerships, the company's progress and strategic planning position it well for future commercialization and growth.Read More>BEAT Stock 12 Month Forecast
Average Price Target
$8.00
▲(540.00%Upside)